Switch theme
Sign up to access all valuation multiples
2cureX AB is a biotech company. The company is engaged in improving treatment efficiency, mainly for cancer patients. It is involved in developing a product, namely IndiTreat, which is a technology for the treatment of colorectal, ovarian, and pancreatic cancers. The company's sub-products include IndiTreat Test, IndiTreat clinical programs, and IndiTreat Therapy Design.
2006
14
Last FY Revenue n/a
Last FY EBITDA -$0.5M
$5.7M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
In the most recent fiscal year, 2cureX achieved revenue of n/a and an EBITDA of -$0.5M.
2cureX expects next 12-month revenue of XXX and NTM EBITDA of XXX
See 2cureX valuation multiples based on analyst estimates| NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|
| Revenue | XXX | n/a | XXX | XXX | XXX |
| Gross Profit | XXX | n/a | XXX | XXX | XXX |
| Gross Margin | XXX | n/a | XXX | XXX | XXX |
| EBITDA | XXX | -$0.5M | XXX | XXX | XXX |
| EBITDA Margin | XXX | n/a | XXX | XXX | XXX |
| EBIT | XXX | -$0.5M | XXX | XXX | XXX |
| EBIT Margin | XXX | n/a | XXX | XXX | XXX |
| Net Profit | XXX | -$0.4M | XXX | XXX | XXX |
| Net Margin | XXX | n/a | XXX | XXX | XXX |
| Net Debt | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, 2cureX's stock price is SEK 2 (or $0).
2cureX has current market cap of SEK 60.7M (or $6.3M), and EV of SEK 55.6M (or $5.7M).
See 2cureX trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $5.7M | $6.3M | XXX | XXX | XXX | XXX | n/a |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, 2cureX has market cap of $6.3M and EV of $5.7M.
2cureX's trades at 358.8x EV/Revenue multiple, and -11.7x EV/EBITDA.
Equity research analysts estimate 2cureX's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
2cureX's P/E ratio is not available.
See valuation multiples for 2cureX and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $6.3M | XXX | $6.3M | XXX | XXX | XXX |
| EV (current) | $5.7M | XXX | $5.7M | XXX | XXX | XXX |
| EV/Revenue | n/a | XXX | 358.8x | XXX | XXX | XXX |
| EV/EBITDA | n/a | XXX | -11.7x | XXX | XXX | XXX |
| EV/EBIT | n/a | XXX | -11.7x | XXX | XXX | XXX |
| EV/Gross Profit | n/a | XXX | n/a | XXX | XXX | XXX |
| P/E | n/a | XXX | -14.7x | XXX | XXX | XXX |
| EV/FCF | n/a | XXX | -12.0x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free Trial2cureX's revenue per employee in the last FY averaged n/a, while opex per employee averaged $35K for the same period.
2cureX's rule of 40 is unknown (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
2cureX's rule of X is unknown (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for 2cureX and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | n/a | XXX | n/a | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | n/a | XXX | XXX | XXX |
| EBITDA Growth | n/a | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | n/a | XXX | n/a | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | n/a | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $35K | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
2cureX acquired XXX companies to date.
Last acquisition by 2cureX was XXXXXXXX, XXXXX XXXXX XXXXXX . 2cureX acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was 2cureX founded? | 2cureX was founded in 2006. |
| Where is 2cureX headquartered? | 2cureX is headquartered in Sweden. |
| How many employees does 2cureX have? | As of today, 2cureX has 14 employees. |
| Is 2cureX publicy listed? | Yes, 2cureX is a public company listed on STO. |
| What is the stock symbol of 2cureX? | 2cureX trades under 2CUREX ticker. |
| When did 2cureX go public? | 2cureX went public in 2017. |
| Who are competitors of 2cureX? | Similar companies to 2cureX include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of 2cureX? | 2cureX's current market cap is $6.3M |
| Is 2cureX profitable? | Yes, 2cureX is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
